Results 161 to 170 of about 148,764 (203)

Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs

Cancer Chemotherapy and Pharmacology, 2019
Cancer caused by fundamental defects in cell cycle regulation leads to uncontrolled growth of cells. In spite of the treatment with chemotherapeutic agents of varying nature, multiple resistance mechanisms are identified in cancer cells. Similarly, numerous variations, which decrease the metabolism of chemotherapeutics agents and thereby increasing the
Vinay Sharma, Sonu Kumar Gupta, Malkhey Verma   +2 more
openaire   +2 more sources

Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population

Cancer Chemotherapy and Pharmacology, 2004
5-Fluorouracil (5-FU) remains the most frequently used chemotherapy agent in various human cancers. Over 80% of the 5-FU administered is metabolized by dihydropyrimidine dehydrogenase (DPD) in the liver. However, mutations in the DPD gene have been found to be associated with low DPD activity causing severe complications.
Hui-Hua, Hsiao, Ming-Yu, Yang, Jan-Gowth, Chang, Yi-Chang, Liu, Ta-Chih, Liu, Chao-Sung, Chang, Tyen-Po, Chen, Sheng-Fung, Lin   +7 more
openaire   +2 more sources

Crystallization and preliminary X-ray study of pig liver dihydropyrimidine dehydrogenase

Acta Crystallographica Section D: Biological Crystallography, 2001
Dihydropyrimidine dehydrogenase catalyzes the first and rate-limiting reaction in pyrimidine catabolism. The enzyme contains one FMN, one FAD and four Fe-S clusters per subunit of 1025 amino acids as prosthetic groups. It is also the major determinant of
Doreen Dobritzsch, Karina Persson, Ylva Lindqvist   +2 more
exaly   +2 more sources

The activity of dihydropyrimidine dehydrogenase in human blood cells

Clinical Biochemistry, 1997
Dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2) is the initial and rate-limiting enzyme in the catabolism of the pyrimidine bases and it catalyses the reduction of thymine and uracil to 5,6-dihydrothymine and 5,6-dihydrouracil, respectively. In children the deficiency of DPD (McKusick 274270) is often accompanied by a neurological disorder, but a ...
van Kuilenburg, A. B., Blom, M. J., van Lenthe, H., Mul, E., van Gennip, A. H.   +4 more
openaire   +4 more sources

Dihydropyrimidine Dehydrogenase Deficiency in a Hutterite Newborn

1991
We have previously described three inherited biochemical disorders in the Hutterite Brethren of Western Canada. These include hypophosphatasia, mucopolysaccharidosis IVA (Morquio Syndrome)1 and methylmalonic acidemia2. A urine specimen from the patient described in this paper came to the Biochemical Genetics Laboratory for a routine metabolic screen. A
K J, Adolph, E, Fung, D R, McLeod, K, Morgan, F F, Snyder   +4 more
openaire   +2 more sources

The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer

BJU International, 2007
OBJECTIVE To measure dihydropyrimidine dehydrogenase (DPD), an enzyme involved in the metabolism of 5‐fluorouracil (5‐FU), expression in prostate cancer and determine whether 5‐chloro‐2,4‐dihydroxypyridine (CDHP), a potent inhibitor of DPD, enhances the antitumoral activity of 5‐FU against prostate cancer.
Yongnan, Li, Yoichi, Mizutani, Takumi, Shiraishi, Terukazu, Nakamura, Kazuya, Mikami, Natsuki, Takaha, Koji, Okihara, Akihiro, Kawauchi, Toshiyuki, Sakai, Tsuneharu, Miki   +9 more
openaire   +2 more sources

Indirect assessment of dihydropyrimidine dehydrogenase activity in cats

Veterinary and Comparative Oncology, 2013
AbstractUse of 5‐fluoropyridimine antimetabolite drugs, specifically 5‐fluorouracil (5‐FU), has been discouraged in cats because of adverse events including neurotoxicity and death. Causes of toxicity have never been elucidated. In humans, toxicity has been associated with ineffective metabolism secondary to deficiencies in dihydropyrimidine ...
C F, Saba, C W, Schmiedt, K G, Freeman, G L, Edwards   +3 more
openaire   +2 more sources

Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase in Bladder Cancer

Urologia Internationalis, 2002
Thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) levels in transitional cell carcinoma of the bladder resected from 38 patients were examined by ELISA. TP levels in high-grade and invasive cancer were significantly higher than those in low-grade and superficial cancer, respectively.
Tatsuo, Iizumi, Kyouichi, Hariu, Mika, Sato, Satoshi, Sato, Hirofumi, Shimizu, Hiroshi, Tomomasa, Takashi, Umeda   +6 more
openaire   +2 more sources

Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency

Human Genetics, 1999
Dihydropyrimidine dehydrogenase (DPD) deficiency is an autosomal recessive disease characterised by thymine-uraciluria in homozygous deficient patients and has been associated with a variable clinical phenotype. In order to understand the genetic and phenotypic basis for DPD deficiency, we have reviewed 17 families presenting 22 patients with complete ...
Kuilenburg, A.B.P. van, Vreken, P., Abeling, N.G.G.M., Bakker, H., Meinsma, R., Lenthe, G.H. van, Abreu, R.A. de, Smeitink, J.A.M., Kayserili, H., Apak, M.Y., Christensen, E., Holopainen, I., Pulkki, K., Riva, D., Botteon, G., Holme, E., Tulinius, M., Kleijer, W.J., Beemer, F.A., Duran, M., Niezen-Koning, K.E., Smit, G.P., Jakobs, C., Smit, L.M.E., Moog, U., Spaapen, L.J., Gennip, A.H. van   +26 more
openaire   +4 more sources

Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2003
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5FU). A deficiency of DPD is increasingly being recognized as the cause of an important pharmacogenetic syndrome. The importance of DPD deficiency in the aetiology of unexpected severe 5FU toxicity has been demonstrated by the fact that ...
André B P, van Kuilenburg, Ronney A, De Abreu, Albert H, van Gennip   +2 more
openaire   +2 more sources